Compounds > murucoidin v
Page last updated: 2024-11-12

murucoidin v

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

murucoidin V: from morning glory; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11607781
CHEMBL ID505000
MeSH IDM0571813

Synonyms (3)

Synonym
CHEMBL505000
murucoidin v
(-)-murucoidin v
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID646202Inhibition of p-glycoprotein expression in vinblastine-sensitive human MCF7 cells at 25 ug/ml after 24 hrs by by immunofluorescence flow cytometry relative to control2012Journal of natural products, Jan-27, Volume: 75, Issue:1
Reversal of multidrug resistance by morning glory resin glycosides in human breast cancer cells.
AID646199Inhibition of p-glycoprotein in vinblastine-sensitive human MCF7 cells assessed as decrease in rhodamine 123 accumulation at 25 ug/ml after 30 mins by flow cytometry2012Journal of natural products, Jan-27, Volume: 75, Issue:1
Reversal of multidrug resistance by morning glory resin glycosides in human breast cancer cells.
AID405927Cytotoxicity against human Hep2 cells after 72 hrs2008Journal of natural products, Jun, Volume: 71, Issue:6
Inhibitors of bacterial multidrug efflux pumps from the resin glycosides of Ipomoea murucoides.
AID1168865Multidrug resistance reversal activity in human KB/VCR cells assessed as vinblastine IC50 at 25 uM incubated for 72 hrs by sulforhodamine B assay (Rvb vinblastine alone IC50 = 0.57 uM)2014Journal of natural products, Oct-24, Volume: 77, Issue:10
Merremins A-G, resin glycosides from Merremia hederacea with multidrug resistance reversal activity.
AID646192Reversal of p-glycoprotein-mediated drug resistant in vinblastine-resistant human MCF7 cells assessed as ratio of IC50 for vinblastin to IC50 for vinblastin in presence of compound at 25 ug/ml after 72 hrs by SRB assay2012Journal of natural products, Jan-27, Volume: 75, Issue:1
Reversal of multidrug resistance by morning glory resin glycosides in human breast cancer cells.
AID405926Cytotoxicity against human KB cells after 72 hrs2008Journal of natural products, Jun, Volume: 71, Issue:6
Inhibitors of bacterial multidrug efflux pumps from the resin glycosides of Ipomoea murucoides.
AID646201Inhibition of p-glycoprotein in vinblastine-sensitive human MCF7 cells assessed as decrease in rhodamine 123 accumulation at 25 ug/ml after 30 mins followed by washout measured after 90 hrs by flow cytometry2012Journal of natural products, Jan-27, Volume: 75, Issue:1
Reversal of multidrug resistance by morning glory resin glycosides in human breast cancer cells.
AID405925Antimicrobial activity against Staphylococcus aureus ATCC 259232008Journal of natural products, Jun, Volume: 71, Issue:6
Inhibitors of bacterial multidrug efflux pumps from the resin glycosides of Ipomoea murucoides.
AID405930Antimicrobial activity against multidrug-resistant Staphylococcus aureus over expressing NorA MDR efflux pump2008Journal of natural products, Jun, Volume: 71, Issue:6
Inhibitors of bacterial multidrug efflux pumps from the resin glycosides of Ipomoea murucoides.
AID646193Reversal of p-glycoprotein-mediated drug resistant in human MCF7 cells grown in vinblastine-free medium assessed as ratio of IC50 for vinblastin to IC50 for vinblastin in presence of compound at 25 ug/ml after 72 hrs by SRB assay2012Journal of natural products, Jan-27, Volume: 75, Issue:1
Reversal of multidrug resistance by morning glory resin glycosides in human breast cancer cells.
AID1168866Multidrug resistance reversal activity in human KB/VCR cells assessed as reduction in vinblastine IC50 at 25 uM incubated for 72 hrs by sulforhodamine B assay relative to untreated control2014Journal of natural products, Oct-24, Volume: 77, Issue:10
Merremins A-G, resin glycosides from Merremia hederacea with multidrug resistance reversal activity.
AID405928Cytotoxicity against human HeLa cells after 72 hrs2008Journal of natural products, Jun, Volume: 71, Issue:6
Inhibitors of bacterial multidrug efflux pumps from the resin glycosides of Ipomoea murucoides.
AID375986Cytotoxicity against human Hep2 cells after 72 hrs by SRB method2006Journal of natural products, Apr, Volume: 69, Issue:4
Resin glycosides from the flowers of Ipomoea murucoides.
AID646194Reversal of p-glycoprotein-mediated drug resistant in vinblastine-sensitive human MCF7 cells assessed as ratio of IC50 for vinblastin to IC50 for vinblastin in presence of compound at 25 ug/ml after 72 hrs by SRB assay2012Journal of natural products, Jan-27, Volume: 75, Issue:1
Reversal of multidrug resistance by morning glory resin glycosides in human breast cancer cells.
AID405929Antimicrobial activity against epidemic methicillin-resistant Staphylococcus aureus 15 containing mecA gene2008Journal of natural products, Jun, Volume: 71, Issue:6
Inhibitors of bacterial multidrug efflux pumps from the resin glycosides of Ipomoea murucoides.
AID1168864Toxicity against human KB/VCR cells assessed as inhibition of cell growth at 25 uM incubated for 72 hrs by sulforhodamine B assay2014Journal of natural products, Oct-24, Volume: 77, Issue:10
Merremins A-G, resin glycosides from Merremia hederacea with multidrug resistance reversal activity.
AID405924Antimicrobial activity against methicillin-resistant Staphylococcus aureus XU2122008Journal of natural products, Jun, Volume: 71, Issue:6
Inhibitors of bacterial multidrug efflux pumps from the resin glycosides of Ipomoea murucoides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's4 (66.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.79 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
octanoic acid
octanoic acid: RN given refers to parent cpd; structure in Merck Index, 9th ed, #1764. octanoic acid : A straight-chain saturated fatty acid that is heptane in which one of the hydrogens of a terminal methyl group has been replaced by a carboxy group. Octanoic acid is also known as caprylic acid.		2.0810medium-chain fatty acid;
straight-chain saturated fatty acid		antibacterial agent;
Escherichia coli metabolite;
human metabolite
norfloxacin
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.. norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.		2.0410fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug;
DNA synthesis inhibitor;
environmental contaminant;
xenobiotic
reserpine
Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.. reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.		2.4620alkaloid ester;
methyl ester;
yohimban alkaloid		adrenergic uptake inhibitor;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
first generation antipsychotic;
plant metabolite;
xenobiotic
vinblastine
[no description available]		2.4420
lissamine rhodamine b
lissamine rhodamine B: RN given refers to parent cpd; Lissamine Rhodamine B refers to Na salt		2.0710
caprylates
Caprylates: Derivatives of caprylic acid. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain a carboxy terminated eight carbon aliphatic structure.. octanoate : A straight-chain saturated fatty acid anion that is the conjugate base of octanoic acid (caprylic acid); believed to block adipogenesis.		2.0810fatty acid anion 8:0;
straight-chain saturated fatty acid anion		human metabolite;
Saccharomyces cerevisiae metabolite
e-z cinnamic acid
cinnamic acid : A monocarboxylic acid that consists of acrylic acid bearing a phenyl substituent at the 3-position. It is found in Cinnamomum cassia.. trans-cinnamic acid : The E (trans) isomer of cinnamic acid		2.0810cinnamic acidplant metabolite
glycosides
[no description available]		3.0240
glycolipids
[no description available]		2.110
operculinic acid
operculinic acid: from the leaves of the native North American prairie plant Ipomoea leptophylla (big root morning glory), shows in vitro activity against M. tuberculosis; structure in first source		2.0810
tetracycline
Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.		2.0410
ConditionIndicatedRelationship StrengthStudiesTrials
Health Care Associated Infection
[description not available]		02.0810
Cross Infection
Any infection which a patient contracts in a health-care institution.		02.0810